W. Kuhn

C. Reiners, H. Coenen, T. Müller, 1997, Journal of investigative medicine : the official publication of the American Federation for Clinical Research.

102. SPET evaluation of [123I]-2 β-carbomethoxy-3 β-(4-iodophenyl)-tropane ([123I]β-CIT) in patients with suspicion of Parkinsonʼs disease

H. Przuntek, H. Coenen, T. Müller, 1996 .

The activity of Catechol-O-Methyltransferase in parkinsonian patients with "on-off fluctuations"

H. Przuntek, D. Woitalla, W. Kuhn, 2000, Journal of Neural Transmission.

Evaluation of the gamma-synuclein gene in German Parkinson's disease patients.

R. Krüger, L. Schöls, H. Przuntek, 2001, Neuroscience letters.

Tolcapone and neurotoxicity in Parkinson's disease

M. Gerlach, D. Woitalla, W. Kuhn, 1998, The Lancet.

Unaltered respiratory chain enzyme activity and mitochondrial DNA in skeletal muscle from patients with idiopathic Parkinson's syndrome.

H. Reichmann, L. Schöls, H. Przuntek, 1994, European neurology.

Huntington's disease: biochemical prediction by determination of GABA synthesis of cultured fibroblasts

H. Przuntek, W. Kuhn, H. Höhn, 2004, Journal of Neurology.

No Vitamin D Deficiency in Patients with Parkinson’s Disease

T. Müller, W. Kuhn, G. Karp, 2021, Degenerative neurological and neuromuscular disease.

Psychomotor investigations in depressed patients by comparison with Parkinson patients

G. Laux, W. Kuhn, W. Classen, 1989 .

Abstracts Second Congress of the European Society for Clinical Neuropharmacology

K. Jellinger, L. Iversen, K. Lesch, 1995, Journal of Neural Transmission / General Section JNT.

[Non-motor symptoms of Parkinson disease. Significant impact on quality of life--using possible treatments].

H. Przuntek, W. Kuhn, T. Müller, 1997, Fortschritte der Medizin.

Tolcapone increases maximum concentration of levodopa

H. Przuntek, D. Woitalla, S. Peters, 2000, Journal of Neural Transmission.

Familial parkinsonism with synuclein pathology: Clinical and PET studies of A30P mutation carriers

R. P. Maguire, R. Krüger, L. Schöls, 2001 .

Alterations in chromatic contour perception in de novo parkinsonian patients.

H. Przuntek, W. Kuhn, T. Büttner, 1995, European neurology.

R- and S-salsolinol are not increased in cerebrospinal fluid of Parkinsonian patients

H. Przuntek, W. Kuhn, H. Rommelspacher, 1999, Journal of the Neurological Sciences.

Plasma levels of R- and S-salsolinol are not increased in "de-novo" Parkinsonian patients

H. Przuntek, D. Woitalla, W. Kuhn, 1998, Journal of Neural Transmission.

No increase of synthesis of (R)salsolinol in Parkinson's disease

H. Przuntek, W. Kuhn, H. Rommelspacher, 1999, Movement disorders : official journal of the Movement Disorder Society.

Aminoadamantanes: from treatment of Parkinson’s and Alzheimer’s disease to symptom amelioration of long COVID-19 syndrome?

P. Riederer, T. Müller, Thomas Müller, 2023, Expert review of clinical pharmacology.

Interleukin-1 beta and interleukin-6 are elevated in the cerebrospinal fluid of Alzheimer's and de novo Parkinson's disease patients.

P Riederer, H. Przuntek, P. Riederer, 1995, Neuroscience letters.

Randomized, double-blind, placebo-controlled trial on symptomatic effects of coenzyme Q(10) in Parkinson disease.

A. Kupsch, W. Oertel, H. Reichmann, 2007, Archives of neurology.

Evaluating ADS5102 (amantadine) for the treatment of Parkinson’s disease patients with dyskinesia

T. Müller, W. Kuhn, Jan-Dominique Möhr, 2019, Expert opinion on pharmacotherapy.

S-100 protein: serum marker of focal brain damage after ischemic territorial MCA infarction.

R. Sprengelmeyer, S. Weyers, W. Kuhn, 1997, Stroke.

Deprenyl — Past and Future

H. Przuntek, W. Kuhn, P. Kraus, 1996, Journal of Neural Transmission.

Basic science in Parkinson’s disease: its impact on clinical practice

J. Schulz, P. Riederer, M. Gerlach, 2011, Journal of Neurology.

Repeat intrathecal triamcinolone acetonide application is beneficial in progressive MS patients

H. Przuntek, C. Lukas, W. Kuhn, 2006, European journal of neurology.

Hyperglycemic Choreoathetosis: Role of the Putamen in Pathogenesis

T. Müller, W. Kuhn, 2009 .

Increased susceptibility to sporadic Parkinson's disease by a certain combined α‐synuclein/apolipoprotein E genotype

R. Krüger, L. Schöls, D. Berg, 1999, Annals of neurology.

Familial parkinsonism with synuclein pathology

R. Krüger, L. Schöls, K. Leenders, 2001, Neurology.

Memantine for Treatment of Dementia

W. Kuhn, T. Müller, 2022, NeuroPsychopharmacotherapy.

Depression in Parkinson's disease: biogenic amines in CSF of “de novo” patients

H. Przuntek, M. Gerlach, W. Kuhn, 2005, Journal of Neural Transmission.

Clinical and biochemical characteristics of early depression in Parkinson’s disease

H. Przuntek, R. Rupprecht, G. Laux, 1989 .

Intravenously Administered Acetylsalicylic Acid in Combination with Low‐Dose Heparin in Acute Ischemic Stroke: A Safety Analysis

W. Kuhn, T. Büttner, K. Hellwig, 1998, Clinical neuropharmacology.

Disgust implicated in obsessive–compulsive disorder

A. Young, A. Calder, R. Sprengelmeyer, 1997, Proceedings of the Royal Society of London. Series B: Biological Sciences.

Iron Deposits in the Subthalamic Nuclei in Hallervorden-Spatz Disease

H. Przuntek, W. Kuhn, T. Müller, 1999, European Neurology.

Levodopa-associated increase of homocysteine levels and sural axonal neurodegeneration.

W. Kuhn, T. Müller, K. Renger, 2004, Archives of neurology.

No increased chromosomal damage in l-DOPA-treated patients with Parkinson’s disease: a pilot study

S. Walitza, M. Gerlach, G. Fazeli, 2010, Journal of Neural Transmission.

Integrity of the blood–cerebrospinal fluid barrier in early Parkinson's disease

H. Przuntek, W. Kuhn, P. Haussermann, 2001, Neuroscience Letters.

Urinary dopamine sulfate conjugates in Parkinson’s disease

K. Jellinger, P. Riederer, W. Danielczyk, 1990 .

Urinary dopamine sulfate: regulations and significance in neurological disorders.

K. Jellinger, P. Riederer, G. Laux, 1990, Journal of neural transmission. Supplementum.

Therapy with central active catechol-O-methyltransferase (COMT)-inhibitors: is addition of monoamine oxidase (MAO)-inhibitors necessary to slow progress of neurodegenerative disorders?

H. Przuntek, W. Kuhn, T. Müller, 2005, Journal of Neural Transmission / General Section JNT.

Evaluation of the γ-synuclein gene in German Parkinson's disease patients

R. Krüger, L. Schöls, H. Przuntek, 2001, Neuroscience Letters.

The effect of R‐(−)‐deprenyl in de novo parkinsonian patients pretreated with levodopa and decarboxylase inhibitor correlated to depression and MHPG, HIAA and HVA levels in the cerebrospinal fluid

H. Przuntek, W. Kuhn, P. Kraus, 1989, Acta neurologica Scandinavica. Supplementum.

Facial expression recognition in people with medicated and unmedicated Parkinson’s disease

H. Przuntek, A. W. Young, A. Young, 2003, Neuropsychologia.

Chromatic and achromatic visual evoked potentials in Parkinson's disease.

H. Przuntek, W. Kuhn, T. Büttner, 1996, Electroencephalography and clinical neurophysiology.

Endogenous benzodiazepine ligands in human cerebrospinal fluid

H. Przuntek, J. Deckert, W. Kuhn, 1984, Peptides.

Genetic influence on the development of Parkinson’s disease

R. Krüger, O. Riess, W. Kuhn, 2000, Journal of Neurology.

Disturbance of colour perception in Parkinson's disease

H. Przuntek, W. Kuhn, T. Büttner, 1993, Journal of neural transmission. Parkinson's disease and dementia section.

Glutathione S-transferase polymorphism in Parkinson's disease

H. Przuntek, H. Bolt, W. Kuhn, 2000, Journal of Neural Transmission.

The N-methyl-D-aspartate antagonist memantine retards progression of Huntington's disease.

M. Gerlach, W. Kuhn, M. Dose, 2004, Journal of neural transmission. Supplementum.

Serum levels of neuron-specific enolase and s-100 protein after single tonic-clonic seizures

H. Przuntek, W. Kuhn, T. Postert, 1999, Journal of Neurology.

Sustained-release of levodopa: single dose study of a new formulation

H. Przuntek, M. Gerlach, W. Kuhn, 2005, Journal of Neural Transmission.

single dose study of a new formulation

H. Przuntek, M. Gerlach, W. Kuhn, 1996 .

L-dopa improves colour vision in Parkinson's disease

H. Przuntek, W. Kuhn, T. Büttner, 1994, Journal of neural transmission. Parkinson's disease and dementia section.

Intravenous amantadine sulphate application improves the performance of complex but not simple motor tasks in patients with Parkinson's disease

H. Przuntek, W. Kuhn, T. Müller, 2003, Neuroscience Letters.

Increased Risk of Parkinson's Disease in Relatives of Patients

H. Przuntek, P. Vieregge, W. Kuhn, 1995, Annals of neurology.

Distorted color discrimination in ‘de nova’ parkinsonian patients

H. Przuntek, W. Kuhn, T. Büttner, 1995, Neurology.

Platelet Monoamine Oxidase B Activity in “de novo” and L-Dopa Treated Parkinsonian Patients and Controls

W. Kuhn, T. Müller, A. Gerstner, 1998, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.

Colour vision abnormalities and movement time in Parkinson's disease

W. Kuhn, T. Büttner, T. Müller, 1999, European journal of neurology.

Impaired Visual Function in Focal Idiopathic Dystonia

M. Dietz, H. Przuntek, W. Kuhn, 1999, European Neurology.

Impaired colour discrimination in Huntington's disease

H. Przuntek, W. Kuhn, S. Schulz, 1994, European journal of neurology.

Levodopa Intake Increases Plasma Levels of S-Adenosylmethionine in Treated Patients With Parkinson Disease

W. Kuhn, T. Müller, B. Fowler, 2005, Clinical neuropharmacology.

3-OMD and homocysteine plasma levels in parkinsonian patients

D. Woitalla, W. Kuhn, B. Fowler, 2002, Journal of Neural Transmission.

The motor performance test series in Parkinson's disease is influenced by depression

H. Przuntek, W. Kuhn, P. Kraus, 2005, Journal of Neural Transmission.

Amantadine for Treating Parkinson’s Disease

W. Kuhn, T. Müller, 2019 .

Angiotensin I converting enzyme in cerebrospinal fluid of patients with neurological diseases

W. Kuhn, H. Schweisfurth, S. Schiöberg-Schiegnitz, 1987, Klinische Wochenschrift.

Aspirin as a free radical scavenger: consequences for therapy of cerebrovascular ischemia.

M. Gerlach, W. Kuhn, T. Müller, 1995, Stroke.

Generators of brain electrical activity in patients with Wilson’s disease

T. Dierks, K. Maurer, W. Kuhn, 1999, European Archives of Psychiatry and Clinical Neuroscience.

Delayed motor response correlates with striatal degeneration in Parkinson's disease

H. Przuntek, E. Eising, W. Kuhn, 1999, Acta neurologica Scandinavica.

[3H] Diazepam Displacing Activity in Human Cerebrospinal Fluid

W. Kuhn, Horst Przuntek, Dieter Neuser, 1981, Journal of neurochemistry.

Efficacy of budipine and placebo in untreated patients with Parkinson’s disease

H. Przuntek, W. Kuhn, T. Müller, 2005, Journal of Neural Transmission.

Parenteral application of NADH in Parkinson's disease: Clinical improvement partially due to stimulation of endogenous levodopa biosynthesis

H. Przuntek, C. Mattern, W. Kuhn, 2005, Journal of Neural Transmission.

Neuroimmune mechanisms in Parkinson's disease.

W. Kuhn, T. Müller, 1995, Journal of neural transmission. Supplementum.

The interactions of 1-alkyl-4,4-diphenylpiperidines with opiate receptors.

H. Przuntek, M. Gerlach, P. Jutzi, 1983, European journal of pharmacology.

Long-term observation of chronic subsutaneous administration of lisuride in the treatment of motor fluctuations in parkinson's disease

W. Kuhn, P. Klotz, I. Suchy, 1992, Journal of neural transmission. Parkinson's disease and dementia section.

Intravenous application of amantadine and antiparkinsonian efficacy in Parkinsonian patients.

H. Przuntek, W. Kuhn, G. Quack, 1995, Journal of neural transmission. Supplementum.

Homocysteine levels after acute levodopa intake in patients with Parkinson's disease

T. Müller, W. Kuhn, 2009, Movement disorders : official journal of the Movement Disorder Society.

Genetic analysis of the alpha2-macroglobulin gene in early- and late-onset Parkinson's disease.

R. Krüger, D. Berg, H. Przuntek, 2000, Neuroreport.

Comparison of two methods for the determination of substance P immunoreactivity in human cerebrospinal fluid: sulphopropyl-Sephadex ion-exchange chromatography and/or reversed-phase high-performance liquid chromatography combined with radioimmunoassay.

H. Przuntek, W. Kuhn, T. Wallasch, 1988, Journal of chromatography.

Increased GABA synthesis in skin fibroblasts of patients with Huntington's disease: a possible role of glutamic acid decarboxylase?

H. Przuntek, H. Lange, M. Gerlach, 1996 .

The central catechol-O-methyltransferase inhibitor tolcapone increases striatal hydroxyl radical production in l-DOPA/carbidopa treated rats

P. Riederer, M. Gerlach, K. Sontag, 2009, Journal of Neural Transmission.

Plasma harman and norharman in Parkinson's disease.

W. Kuhn, H. Rommelspacher, H. Grosse, 1995, Journal of neural transmission. Supplementum.

The effect of R-(-)-deprenyl in de novo parkinsonian patients pretreated with levodopa and decarboxylase inhibitor correlated to depression and MHPS, HIAA, and HVA levels of cerebrospinal fluid.

H. Przuntek, W. Kuhn, 1990, Advances in neurology.

Effects of Amantadine Sulfate on Motor Impairment and Execution of Motor Sequences in Patients With Parkinson Disease

T. Müller, W. Kuhn, 2023, Clinical neuropharmacology.